Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability

Journal of Pharmaceutical Sciences

Volumn 86, Issue 12, 1997, Pages 1352-1357

  Tzou, Tsi Zong ^b   Pachuta, Robin R ^b   Coy, Robert B ^b   Schultz, Robert K ^a,b  

^a Dura Pharmaceuticals   (United States)

^b 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; OLEIC ACID; PROPELLANT; SALBUTAMOL; SOLVENT; SULFATE;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; METERED DOSE INHALER; PARTICLE SIZE;

EID: 0031445299     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js970225g     Document Type: Article

References (18)

1. Sciarra, J. J.; Cutie, A. J. Pharmaceutical Aerosols. In The Theory and Practice of Industrial Pharmacy, 3rd ed.; Lachman, L., Lieberman, H. A., Kanig, J. L., Eds.; Lea & Febiger: Philadelphia, 1986; pp 589-618.
2. Dalby, R. N.; Byron, P. R.; Shepherd, H. R.; Papadopoulos, E. CFC Propellant Substitution: P-134a as a Potential Replacement for P-12 in MDIs. Pharm. Technol. 1990, 14, 26-33.
3. Fisher, F. X. CFC Propellant Substitution: International Perspectives. Pharm. Technol. 1989, 1 (2), 16-18.
4. Hallworth, G. W. The formulation and Evaluation of Pressurised Metered-Dose Inhalers. In Drug Delivery to the Respiratory Tract; Ganderton, D., Jones, T. M., Eds.; Ellis Horwood Ltd.: Chichester (England), 1987; pp 87-118.
5. Byron, P. R. Towards the Rational formulation of Metered Dose Inhalers. J. Biopharm. Sci. 1992, 3, 1-9.
6. Phillips, E. M. Crystal Growth - Formulation Dependence and Early Detection. J. Biopharm. Sci. 1992, 3, 11-18.
7. Ranucci, J.; Dixit, S.; Bray, R. N.; Goldman, D. Controlled Flocculation in Metered Dose Inhalers. Pharm Technol. 1990, 14, 68-74.
8. Soine, W. H.; Blondino, F. E.; Byron, P. R. Chemical Stability in Pressurized Inhalers Formulated as Solutions. J. Biopharm. Sci. 1992, 3, 41-47.
9. Mälkki-Laine, L.; Purra, K.; Kähkönen, K.; Tammilehto, S. Decomposition of Salbutamol in Aqueous Solutions. II. The Effect of Buffer Species, pH, Buffer Concentration and Antioxidants. Int J. Pharm. 1995, 117, 189-195, and references therein.
10. Ward, G. H.; Schultz, R. K. Process-Induced Crystallinity Changes in Albuterol Sulfate and Its Effect on Powder Physical Stability. Pharm. Res. 1995, 12 (5), 773-779.
11. Dalby, R. N.; Phillips, E. M.; Byron, P. R. Determination of Drug Solubility in Aerosol Propellants. Pharm. Res. 1991, 8, 1206-1209.
12. Sanders, P. A. Handbook of Aerosol Technology, 2nd ed.; Van Nostrand: New York, 1979; pp 165-187.
13. Schultz, R. K.; Ross, D. L.; Tzou, T.-Z. Assessment of MDI formulations Based on Medication Delivery Techniques. Pharm. Res. 1993, 10, (10), S166.
14. Ward, G. H.; Morken, M. A. The Effect of Environmental Storage Conditions on Physical Property Changes in Micronized Albuterol Sulfate. Pharm. Res. 1995, 12, (9), S183.
15. Blackett, P. M.; Buckton, G. A Micorcalorimetric Investigation of the Interaction of Surfactants with Crystalline and Partially Crystalline Salbutamol Sulphate in a Model Inhalation Aerosol System. Pharm. Res. 1995, 12 (11), 1689-1693.
16. Leung, S. S.; Schultz, D. W. Kinetics of Crystallinity Changes in Micronized Albuterol Sulfate and Terbutaline Sulfate Powders. Pharm. Res. 1996, 13 (9), S345.
17. Schachtner, W. J. Low-Temperature Processing of P134a Aerosols. AAPS Inhalation Technologies Focus Group Meeting, November 5-9, 1995, Miami Beach, FL.
18. Shurkus, D. High-Pressure Production of 134a MDI's. AAPS Inhalation Technologies Focus Group Meeting, November 5-9, 1995, Miami Beach, FL.